Assays for TIMP2 having improved performance in biological samples

• US 9,879,091 B2
• Filed: 08/07/2014
• Issued: 01/30/2018
• Est. Priority Date: 08/07/2013
• Status: Active Grant

• Current Assignee: Astute Medical, Inc. (Compagnie Merieux Alliance SAS)
• Original Assignee: Astute Medical, Inc. (Compagnie Merieux Alliance SAS)
• Inventors: Vijayendran, Ravi A., Venkatasubbarao, Srivatsa
• Primary Examiner(s): Cheu, Jacob
• Application Number:
  US14/910,661
• Publication Number:
  US 20160297893A1
• Time in Patent Office: 1,272 Days
• Field of Search: None
• CPC Class Codes: C07K 16/38 against protease inhibitors of peptide structure
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: G01N 2333/8146 Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence

Abstract

The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

Claims

1. A method for determining the presence or amount of human TIMP2 in a biological sample, comprising:

performing an immunoassay on the biological sample with a first monoclonal antibody and a second monoclonal antibody which together form sandwich complexes with human TIMP2, wherein the immunoassay provides a detectable signal that is related to the presence or amount of human TIMP2 in the biological sample bound in the sandwich complexes; and

relating the detectable signal to the presence or amount of human TIMP2 in the biological sample, wherein one or both of the first monoclonal antibody and second monoclonal antibody—

is a monoclonal antibody that binds with an affinity of at least 10⁸ M<sup>−

1</sup> to a polypeptide, wherein the sequence of said polypeptide consists of a sequence selected from the group consisting of;

2. A method according to claim 1, wherein the minimum detectable concentration of TIMP-2 in the immunoassay is 10 ng/mL or less.

3. A method according to claim 2, wherein the immunoassay is performed in a lateral flow format.

4. A method according to claim 2, wherein the immunoassay is an in vitro diagnostic.

5. A method according to claim 4, wherein the immunoassay is performed by applying the human patient sample to a disposable test device, and the detectable signal is obtained by inserting the disposable test device into an analytical instrument, wherein the sandwich complexes comprising the first and second antibodies are immobilized for detection in a predetermined zone of the disposable test device, and wherein the analytical instrument detects the immobilized sandwich complexes to provide the detectable signal.

6. A method according to claim 2, wherein the first antibody is conjugated to a signal development element.

7. A method according to claim 6, wherein the first antibody forms a reaction mixture with the human patient sample, and the human patient sample is applied to the disposable test device by applying the reaction mixture to the disposable test device.

8. A method according to claim 6, wherein the second antibody is immobilized at the predetermined zone of a solid support.

9. A method according to claim 2, wherein each of the first and second antibodies is a rabbit, mouse, chicken, goat, sheep, donkey, human, llama or camelid antibody.

10. A method according to claim 2, wherein each of the first and second antibodies is a rabbit antibody.

11. A method according to claim 2, wherein each of the first and second antibodies is a monoclonal antibody that binds with an affinity of at least 10⁸ M⁻

1 to a polypeptide, wherein the sequence of said polypeptide consists of a sequence selected from the group consisting of;